Apparatuses and systems are provided which include one or more receptacles for receiving drugs and further include one or more stored supplies of one or more absorbent materials comprising crosslinkers, wherein the apparatus and systems are adapted to release the absorbent materials comprising crosslinkers into the one or more receptacles. A method is provided which includes depositing a drug into a predetermined amount of fluid and adding to the drug containing fluid a absorbent material comprising crosslinkers which is capable of encapsulating the drug containing fluid and possibly killing infectious materials within the fluid and/or denaturing the drug within the fluid.

The invention relates to a method for producing an aqueous foam comprising the following steps: (a) preparing a solution comprising at least one surfactant and at least one protic polar solvent, (b) bringing the solution into contact with a pressurised gas, whereby a two-phase mixture is obtained, and (c) injecting the two-phase mixture, whereby, after expansion or dispersion of the gas, the aqueous foam is obtained. According to the invention, the solution further comprises at least one gelling compound chosen from a non-nitrogenous polysaccharide and gelatin. The invention also relates to the aqueous foam obtained by such a method and to the uses of same, in particular in the fields of decontamination, the purification of effluents, or the defusing or containment of explosive devices or suspected explosive devices.

The invention relates to a method for producing an aqueous foam comprising the following steps: (a) preparing a solution comprising at least one surfactant and at least one protic polar solvent, (b) bringing the solution into contact with a pressurised gas, whereby a two-phase mixture is obtained, and (c) injecting the two-phase mixture, whereby, after expansion or dispersion of the gas, the aqueous foam is obtained. According to the invention, the solution further comprises at least one gelling compound chosen from a non-nitrogenous polysaccharide and gelatin. The invention also relates to the aqueous foam obtained by such a method and to the uses of same, in particular in the fields of decontamination, the purification of effluents, or the defusing or containment of explosive devices or suspected explosive devices.

A batch process of remediation of soil and sediment contaminated with toxic metals includes the steps of treating contaminated soil and sediment with a solution containing aminopolycarboxylic chelating agent, rinsing the soil/sediment solid phase to remove residues of mobilized toxic metals, treating the used process waters to recycle chelating agent and clean process solutions and placing the remediated soil/sediment on a permeable horizontal reactive barrier to prevent emission of contaminants. In the batch process, toxic metals are removed from process solutions by alkaline adsorption of polysaccharide adsorbents. By applying alkaline adsorption the efficiency of toxic metal removal from process solutions and alkaline and acidic recycling of chelating agent is significantly improved.

A batch process of remediation of soil and sediment contaminated with toxic metals includes the steps of treating contaminated soil and sediment with a solution containing aminopolycarboxylic chelating agent, rinsing the soil/sediment solid phase to remove residues of mobilized toxic metals, treating the used process waters to recycle chelating agent and clean process solutions and placing the remediated soil/sediment on a permeable horizontal reactive barrier to prevent emission of contaminants. In the batch process, toxic metals are removed from process solutions by alkaline adsorption of polysaccharide adsorbents. By applying alkaline adsorption the efficiency of toxic metal removal from process solutions and alkaline and acidic recycling of chelating agent is significantly improved.

A device for storage and disposal of embalming procedure waste from an embalming procedure of an animal or human corpse. The device includes an inlet for receiving the embalming procedure waste and an encapsulate storage unit configured for holding absorbent encapsulate. The device further includes a mixing unit fluidly connected to the inlet and the encapsulate storage unit, a diverter device connected to the mixing unit and at least one storage unit configured to receive and store the embalming procedure waste from the diverter device.

A device for storage and disposal of embalming procedure waste from an embalming procedure of an animal or human corpse. The device includes an inlet for receiving the embalming procedure waste and an encapsulate storage unit configured for holding absorbent encapsulate. The device further includes a mixing unit fluidly connected to the inlet and the encapsulate storage unit, a diverter device connected to the mixing unit and at least one storage unit configured to receive and store the embalming procedure waste from the diverter device.

A medication disposal apparatus includes a collection chamber to receive a medication having an active agent. The collection chamber includes a receiver having a one-way opening. The one-way opening receives the medication in the collection chamber and to impede the medication from exiting the collection chamber through the receiver. The collection chamber includes a first converter to receive the medication and/or convert the medication into a plurality of particles. The first converter is housed in the collection chamber and/or may receive the medication from the collection chamber. The first converter has a grinder with a plurality of rollers operable to convert the medication into the plurality of particles. The first converter includes a motor powered by a power source. The apparatus includes a reservoir fastened to the collection chamber and apparatus includes a second converter.

A medication disposal apparatus includes a collection chamber to receive a medication having an active agent. The collection chamber includes a receiver having a one-way opening. The one-way opening receives the medication in the collection chamber and to impede the medication from exiting the collection chamber through the receiver. The collection chamber includes a first converter to receive the medication and/or convert the medication into a plurality of particles. The first converter is housed in the collection chamber and/or may receive the medication from the collection chamber. The first converter has a grinder with a plurality of rollers operable to convert the medication into the plurality of particles. The first converter includes a motor powered by a power source. The apparatus includes a reservoir fastened to the collection chamber and apparatus includes a second converter.

Provided are astexin-1, astexin-2 and astexin-3 lasso peptides, which are based on sequences identified in Asticaccaulis excentricus, and methods of making and using same. Astexin-1 is highly polar, in contrast to many lasso peptides that are primarily hydrophobic, and has modest antimicrobial activity against Caulobacter crescentus, a bacterium related to Asticaccaulis excentricus. The solution structure of astexin-1 was determined, revealing a unique topology that is stabilized by hydrogen bonding between segments of the peptide. Astexins-2 and -3 are intracellular lasso peptides.